Top-Line Data from Opexa’s Phase IIb Tovaxin® Study to be Presented at World Congress on Treatment and Research in Multiple Sclerosis
Novel T-Cell Vaccine Being Evaluated as Patient-Specific Treatment for MS
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced that top-line data from the company’s Phase IIb study of Tovaxin® will be presented at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada, on September 19, 2008. Tovaxin, Opexa’s lead product candidate, is a novel T-cell vaccine for the treatment of MS that is specifically tailored to each patient’s disease profile. Clinical results to date have demonstrated that Tovaxin may offer enhanced efficacy, safety and tolerability as compared to other MS therapies currently on the market or in development.
Dr. Edward J. Fox, M.D., Ph.D., director of the Multiple Sclerosis Clinic of Central Texas and the study’s principal investigator, will present top-line results from Opexa’s TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study. The details of Dr. Fox’s presentation are as follows:
TERMS (Tovaxin for Early Relapsing MS) Phase IIb Placebo-Controlled Trial of Autologous T-cell Vaccination in Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
Parallel Session 07 - Emerging Therapies
Friday, September 19, 2008
2:55 - 3:10 p.m. (EST)
Palais des congres de Montreal
Investigator Q&A Session
Opexa will host an investigator Q&A session following the conclusion of the day’s programs on September 19, 2008. The Q&A session will be webcast. For details regarding the Q&A session, please contact Stephanie Diaz of Vida Communication at 415-675-7401 or firstname.lastname@example.org
The World Congress on Treatment and Research in Multiple Sclerosis, the first joint meeting of ACTRIMS (the Americas Committee on Treatment and Research in Multiple Sclerosis) and its counterparts in Europe and Latin America: ECTRIMS and LACTRIMS, will take place September 17-20, 2008, in Montreal, Canada.